PCSA Stock Analysis: Buy, Sell, or Hold?
PCSA - Processa Pharmaceuticals, Inc. Common
$2.08
-0.06 (-3.03%)
▼
5d:
-14.4%
30d:
-27.53%
90d:
-18.91%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 20, 2026
0d
Get Alerted When PCSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PCSA is down 14.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PCSA is down 14.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PCSA is currently trading at $2.08, which is considered oversold relative to its 30-day fair value range of $2.09 to $2.62.
Technical Outlook: Technically, PCSA is in a downtrend. Immediate support is located at $2.00, while resistance sits at $2.79. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.00 (+1065.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCSA is in a downtrend. Immediate support is located at $2.00, while resistance sits at $2.79. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.00 (+1065.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.09 -
$2.62
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 1065.5% below Wall St target ($25.00)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.09 -
$2.62
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.00
Resistance Level
$2.79
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.57
Wall Street Target
$25.00
(+1065.5%)
Share & Embed Analysis
Last updated: August 24, 2026 9:07 AM ET
Data refreshes hourly during market hours. Next update: 10:07 AM
Data refreshes hourly during market hours. Next update: 10:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCSA showing a specific setup today?
Insider Activity (6 Months)
12
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David Young
BUY
1545 shares
2026-04-15
George K Ng
BUY
1843 shares
2026-04-15
Russell Skibsted
BUY
1984 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
